Drug-Induced Liver Injury: A Unique Presentation of Single-Dose Administration of Propylthiouracil

Simcha Weissman, DO1, Nishan G. Rajaratnam, MD1, Nabeel Qureshi, MD1, Faisal Inayat, MBBS2, and Sameh Elias, MD, FACP1

Abstract

Antithyroid drug-induced severe liver injury is an uncommon but serious complication. We hereby delineate the case of a 38-year-old female who presented to the emergency department for an impending thyroid storm. After initiation of a single dose of propylthiouracil, her liver enzymes went into the thousands. She was subsequently admitted to the intensive care unit. Propylthiouracil was discontinued and corticosteroids were initiated with the resolution of her elevated liver enzymes. On follow-up, her liver function was at its baseline and thyroid hormone levels were under control. We hope this report will encourage clinicians to cast a broad differential diagnosis in patients presenting with liver injury in the acute setting. Furthermore, it is imperative to raise awareness regarding the ever-increasing list of pharmacologic agents that can perpetuate drug-induced hepatotoxicity.

Keywords
drug-induced liver injury, hepatic dysfunction, hepatocellular injury, propylthiouracil

Introduction

Drug-induced liver injury (DILI) is an adverse drug reaction characterized by liver injury. While in certain clinical scenarios DILI may only require discontinuation of the offending agent, intensive care unit admission and even liver transplantation are often resulting phenomena.1,2 In fact, DILI is the number one cause of acute liver failure in the United States.3 Although numerous etiologies have been established as culprits of DILI, propylthiouracil (PTU)—an antithyroid medication known to contribute to a mild elevation in liver enzymes—can also lead to hepatotoxicity, a rare phenomenon reported in only 1/10000 individuals.4,5 Despite this, it is even more uncommon in a non-obstetric patient (or in those over age 18 years) and/or occurring as an immediate drug reaction, as the onset of injury has typically been observed 2 to 12 weeks after drug initiation.3,5 In this setting, we present the case of a female with an impending thyroid storm, who developed acute liver injury hours after a single dose of PTU. The aim of this article is to prompt clinicians to cast a broad differential diagnosis in patients presenting with rising liver enzymes in the acute setting, as well as raise awareness as to the ever-increasing list of medications known to perpetuate DILI.

Case Presentation

A 38-year-old female with a history of a multinodular goiter, hyperthyroidism, and iodine allergy presented to the emergency department complaining of palpitations, chest discomfort, and dyspnea. The patient reported that she had recently restarted taking methimazole 10 mg daily after being noncompliant with her medications for the past 3 years. In the emergency department, she was found to be in atrial fibrillation with a rapid ventricular rate and to have an estimated left ventricular ejection fraction of 20%. Laboratory evaluation revealed a suppressed thyroid-stimulating hormone (0.01 mlU/L), elevated free T4 (3.48 ng/dL), elevated free T3 (9.90 pg/mL), and normal liver transaminases. A diagnosis of thyrotoxicosis was made, and treatment with PTU and propranolol was initiated. PTU was chosen due to its inhibition of the peripheral conversion of T4 to T3 and subsequent preference in thyroid storm.

Nine hours after the initial dose of 200 mg PTU, the patient’s aspartate aminotransferase and alanine aminotransferase levels showed significant elevation, eventually peaking at 1127 IU/L and 1004 IU/L, respectively (Figure 1). The patient was then transferred to the intensive care unit for close monitoring. Of

1Hackensack Meridian Health Palisades Medical Center, North Bergen, NJ, USA
2Allama Iqbal Medical College, Lahore, Punjab, Pakistan

Received July 16, 2020. Revised July 22, 2020. Accepted July 25, 2020.

Corresponding Author:
Faisal Inayat, MBBS, Allama Iqbal Medical College, Allama Shabbir Ahmad Usmani Road, Faisal Town, Lahore, Punjab 54700, Pakistan.
Email: faisalinayat@hotmail.com
case was notable for the rapidity with which liver dysfunction occurred—as after just a single dose of PTU a severe elevation in the transaminases ensued.11

Hyperthyroidism and/or her state of hypoperfusion had the potential to cause a rise in liver enzymes. However, liver enzymes of this patient began to normalize while her ejection fraction was still low and amidst an acute episode of thyroid crisis. It is for this reason the authors believe both of those factors did not play a role in the liver injury. Notably, she remained normotensive throughout her clinical course, and liver hypoperfusion, that is, shock liver, can therefore be ruled out as an etiology of her sudden clinically significant hepatic dysfunction. In addition, a hepatitis panel and autoimmune markers were normal, excluding viral hepatitis and/or an autoimmune disease as culprits. Moreover, this patient did not receive acetaminophen or NSAIDs before or during her hospital course, further excluding other known causes of DILI.

The Naranjo scale, an adverse drug reaction assessment score, can be helpful in establishing the degree of association between a drug and an adverse reaction, especially for drug reactions that have not yet been well established or are rarely reported. For our patient, the Naranjo scale score was a 5, rendering DILI a “probable” adverse drug reaction of PTU in this case.12

DILI can occur through several pathophysiologic pathways. Most commonly, hepatocellular damage is intrinsic in nature, as it occurs in a predictable dose-dependent fashion, such as seen with acetaminophen toxicity.13 Conversely, as seen in our case, DILI can occur via an idiosyncratic drug reaction, one that is less predictable and not dose-dependent.13

PTU acts by terminating the production of new thyroid hormone via inhibiting the enzyme thyroid peroxidase, which normally facilitates thyroid hormone production. Importantly, PTU also blocks the peripheral conversion of T4 to T3, making it particularly useful in the setting of thyroid storm. As such, it is the recommended agent for thyroid storm and in women during the first trimester of pregnancy.14

With regard to the treatment of antithyroid drug–associated acute liver injury, no standard therapeutic strategy is available, except for drug discontinuation and liver function monitoring.15,16 Notably, anecdotal clinical evidence exists pertaining to the efficacy of intravascular glutathione for methimazole-related hepatotoxicity.17 Furthermore, Becker and colleagues18 supported the use of corticosteroids in patients with methimazole-associated transaminitis. Prednisolone may also show a response to alleviate antithyroid drug-induced jaundice.15 The patient involved in this study showed improvement in both liver and thyroid functions after corticosteroid treatment. Therefore, corticosteroid use may also be evaluated in DILI secondary to PTU. In selected clinical settings, artificial liver support systems or liver transplantation can also be considered in patients with severe DILI second-
Conclusions
We highlight PTU as a potential cause of hepatotoxicity after just a single dose. Given the high morbidity and lack of definitive risk factors associated with DILI, this case serves as a stark reminder for clinicians to be mindful and check transaminase levels before starting a patient on PTU and to closely monitor these levels in the days and weeks following its initiation, to aid in both primary and secondary prevention.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

Ethics Approval
Our institution does not require ethical approval for reporting individual cases or case series.

Informed Consent
Informed consent was obtained from the patient(s) for their anonymized information to be published in this article.

ORCID iD
Faisal Inayat https://orcid.org/0000-0001-7576-7319

References
1. Ostapowicz G, Fontana RJ, Schiodt FV, et al; US Acute Liver Failure Study Group. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002;137:947-954.
2. David S, Hamilton JP. Drug-induced liver injury. US Gastroenterol Hepatol Rev. 2010;6:73-80.
3. Akmal A, Kung J. Propylthiouracil, and methimazole, and carbimazole-related hepatotoxicity. Expert Opin Drug Saf. 2014;13:1397-1406.
4. Benyounes M, Sempoux C, Daumerie C, Rahier J, Geubel AP. Propylthiouracil-induced severe liver toxicity: an indication for alanine aminotransferase monitoring? World J Gastroenterol. 2006;12:6232-6234.
5. Sequeira E, Wanyonyi S, Dodia R. Severe propylthiouracil-induced hepatotoxicity in pregnancy managed successfully by liver transplantation: a case report. J Med Case Rep. 2011;19:461.
6. Schoepfer AM, Engel A, Fattinger K, et al. Herbal does not mean innocuous: ten cases of severe hepatotoxicity associated with dietary supplements from Herbalife products. J Hepatol. 2007;47:521-526.
7. Itoh S, Marutani K, Nishijima T, Matsuo S, Itabashi M. Liver injuries induced by herbal medicine, syo-saiko-to (xiao-chai-hu-tang). Dig Dis Sci. 1995;40:1845-1848.
8. Andrade RJ, Lucena MI, Fernández MC, et al; Spanish Group for the Study of Drug-Induced Liver Disease. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129:512-521.
9. Nunez M. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. J Hepatol. 2006;44:132-139.
10. Graham DJ, Green L, Senior JR, Nourjah P. Troglitazone-induced liver failure: a case study. Am J Med. 2003;114:299-306.
11. Wu DB, Chen EQ, Bai L, Tang H. Propylthiouracil-induced liver failure and artificial liver support systems: a case report and review of the literature. Ther Clin Risk Manag. 2017;11:65-68.
12. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-245.
13. Wang MT, Lee WJ, Huang TY, Chu CL, Hsieh CH. Antithyroid drug-related hepatotoxicity in hyperthyroidism patients: a population-based cohort study. Br J Clin Pharmacol. 2014;78:619-629.
14. Ramprasad M, Bhattacharyya SS, Bhattacharyya A. Thyroid disorders in pregnancy. Indian J Endocrinol Metab. 2012;16(suppl 2):S167-S170.
15. Gallelli L, Staltari O, Palleria C, De Sarro G, Ferraro M. Hepatotoxicity induced by methimazole in a previously healthy patient. Curr Drug Saf. 2009;4:204-206.
16. Levy M. Propylthiouracil hepatotoxicity. A review and case presentation. Clin Pediatr (Phila). 1993;32:25-29.
17. Yang J, Zhong J, Zhou LZ, Hong T, Xiao XH, Wen GB. Sudden onset agranulocytosis and hepatotoxicity after taking methimazole. Intern Med. 2012;51:2189-2192.
18. Becker CE, Gorden P, Robbins J. Hepatitis from methimazole during adrenal steroid therapy for malignant exophthalmos. JAMA. 1968;206:1787-1789.
19. Lee SO, Choi JK, Kim HS, Seo JS, Ahn DS. A case of similar pattern of hepatotoxicity after propylthiouracil and methimazole. Korean J Hepatol. 1999;5:136-141.
20. Bartnik CM, Maheshwari RN, Subramanian RM. Beating the odds: a full-term delivery after liver transplantation of a pregnant hyperthyroid patient at 19 weeks’ gestation for propylthiouracil-induced acute liver failure. Transplant Proc. 2018;50:3995-3999.